AtriCure stock: 15% Q3 revenue growth supports higher outlook
Published on 11/09/2026 at 03:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly growth and raised outlook
- AtriCure returned to quarterly GAAP profitability as operating income and adjusted EBITDA expanded.
- U.S. demand for pain management, open ablation and appendage management products drove the latest performance.
- Management expects continued positive cash generation while minimally invasive ablation remains under pressure from PFA adoption.
AtriCure reported stronger third-quarter results on November 3, 2026, with worldwide revenue rising 15.0 percent year over year to 154.5 million US dollars. The company also raised its full-year 2026 revenue and adjusted EBITDA outlook in its financial results release.
Profitability expands across franchises
AtriCure generated 4.1 million US dollars of GAAP net income, compared with a 0.3 million US dollar loss in the year-earlier quarter. Adjusted EBITDA rose to 26.8 million US dollars from 17.8 million US dollars, while gross margin increased to 77.3 percent from 75.5 percent.
U.S. revenue increased 17.1 percent to 128.0 million US dollars. Growth came from pain management, open ablation and appendage management products, including the cryoSPHERE MAX probe, the EnCompass clamp and AtriClip devices. International revenue grew 5.8 percent to 26.4 million US dollars.
Guidance points to continued cash generation
Management now expects 2026 revenue of 606 million to 610 million US dollars and adjusted EBITDA of 91 million to 94 million US dollars. GAAP earnings per share are expected at 0.21 to 0.27 US dollars, while adjusted earnings per share are projected at 0.40 to 0.46 US dollars. The company said it expects continued positive cash generation.
The main operating counterpoint is minimally invasive ablation, where sales declined as physicians adopted pulsed-field ablation catheters. That trend adds competitive pressure even as AtriCure expands in pain management, open ablation and left atrial appendage management.
Business model and competitive position
AtriCure, based in Mason, Ohio, develops and sells medical technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Its portfolio includes surgical ablation systems, AtriClip products and cryoablation probes used in cardiac, thoracic and related procedures. In the left atrial appendage closure market, IndexBox identifies Medtronic, LivaNova and Edwards Lifesciences alongside AtriCure; AtriCure is positioned as a surgical specialist, while the others bring broader cardiovascular portfolios or different structural-heart capabilities.
AtriCure at a glance
- Company: AtriCure, Inc.
- Ticker: ATRC
- Primary exchange: Nasdaq
- Reporting period: Third quarter 2026, ended September 30, 2026
- Headquarters: Mason, Ohio, United States
Medical-device investors can compare AtriCure's development with broader trends in the S&P 500 and the healthcare sector.
